Company intelligence / Profile preview

Tri-Jin Biomed

Ownership: Private
Development stage: Other

Overview

Tri-Jin Biomed is a clinical-stage biotechnology company focused on the development of innovative therapies for oncology and inflammatory diseases. The company's pipeline includes several small molecule inhibitors and monoclonal antibodies targeting key pathways in cancer progression and immune evasion. Tri-Jin Biomed is currently advancing its lead programs through Phase 2 clinical trials, with a focus on addressing unmet medical needs in solid tumors. The company leverages its expertise in drug discovery and development to create a robust portfolio of next-generation therapeutics.

Therapeutic areas: Oncology
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on Tri-Jin Biomed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tri-Jin Biomed.

Explore the full profile